The tariff classification of a mechanical insufflation-exsufflation device from the United Kingdom
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the Clearo MI-E device will be 9019.20.0000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “[o]zone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus; parts and accessories thereof.” The general rate of duty will be free.
Ruling text
In your letter dated June 5, 2025, you requested a tariff classification ruling on behalf of Breas Medical, Inc. You state the company is a well-known medical equipment producer of respiratory care devices designed for those with chronic conditions. Clearo MI-E (Mechanical Insufflation-Exsufflation) device is a portable airway clearance device that provides cough modes and therapeutic modes. The cough modes include a manual mode, a basic auto mode, a program auto mode, and a TreatRepeat mode.
The therapeutic modes include an Intermittent Positive Pressure Breathing (IPPB, noncontinuous ventilator) mode, and a non-invasive ventilation mode. The device can also be used for oxygen therapy with IPPB. The device is intended for adult or pediatric patients that have compromised secretion clearance and/or a reduced ability to cough effectively.
Individuals who may benefit from the use of the Clearo MI-E device include any patient with an ineffective cough due to muscular dystrophy, amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), myasthenia gravis, poliomyelitis, other neurologic disorders, and spinal cord injury. The Clearo MI-E device can be used for IPPB and therefore may also be used in patients with bronchopulmonary disease to promote effective secretion removal and or lung volume recruitment.
When used as a mechanical insufflator-exsufflator, it provides a positive pressure to the airway (insufflation), followed rapidly by a negative pressure (exsufflation) to promote the removal of secretions. This is achieved through increasing the expiratory flow from the lungs, in order to replicate normal cough function. Optional oscillatory vibrations may further aid in loosening and mobilizing secretions.
The continued rapid transition to negative pressure helps generate sufficient expiratory flow from the central airways, supporting the clearance of respiratory secretions. The device achieves its intended use through a blower, which compresses air, a solenoid-controlled valve to manage air flow and pressure, and microcontroller electronics to control and monitor the operation. It is powered from either a main source or an internal battery.
The device offers MI-E for both invasively and non-invasively ventilated patients as well as patients who breathe independently. It may be used either with a facemask, mouthpiece, or with a suitable adapter to a patient’s endotracheal or tracheostomy tube (MI-E only). It must only be used non-invasively when using the IPPB mode. Only a facemask or mouthpiece should be used to administer IPPB therapy with the device. The device is intended for use within a hospital, institutional environment, or in the home.
It must be prescribed by a licensed physician and must be used only as directed by a physician or healthcare provider. You state that your client plans to sell this device directly to durable medical equipment suppliers, hospitals (more specifically, their medical equipment at home stores/divisions), medical facilities, and through specialized distributors.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N349868).